BCRX BioCryst Pharmaceuticals, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
BCRX Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
Current Price
Live
$6.79
Analyst Target
$20.5
+201.9%
Upside
52W High
$11.31
52W Low
$6.0
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals significant concerns with a weak Piotroski F-Score of 2/9, indicating poor financial health, and an absent Altman Z-Score, preventing a clear distress risk assessment. Despite this, the company shows strong revenue growth of 36.1% YoY, improving operating margins, and a bullish analyst consensus of 'strong_buy' with a $20.50 target price. However, negative profit margin, insider selling, and lack of key valuation metrics like Graham Number and Altman Z-Score create substantial uncertainty. The stock trades well below its target, suggesting potential upside, but fundamental weaknesses and mixed earnings performance temper optimism.
Key Strengths
Strong YoY revenue growth of 36.10%, outpacing sector average of 62.52% but still in high-growth territory
High gross margin of 68.43%, indicating strong pricing power and cost control in core operations
Improving operating margin at 18.57%, reflecting operational efficiency gains
Bullish analyst consensus with 'strong_buy' rating and high target price of $20.50 vs current $6.79
Recent earnings surprises have been positive, with 3 out of last 4 quarters beating estimates and an average surprise of 63.95%
Key Risks
Very low Piotroski F-Score of 2/9 signals weak financial health, particularly in profitability and leverage stability
Negative profit margin of -1.46% and lack of ROE/ROIC data raise concerns about sustainable profitability
Absence of Altman Z-Score prevents proper bankruptcy risk assessment, a critical red flag for financial stability
Insider selling activity totaling $2.16M over last 6 months indicates lack of confidence from corporate insiders
Price/Sales of 2.39 and negative Price/Book of -3.68 suggest valuation challenges and potential balance sheet issues
AI Fair Value Estimate
Based on comprehensive analysis
$20.5
+201.9% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare BCRX against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning BCRX from our newsroom.
Newest → oldest
No matching news yet.